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Alport syndrome, X-linked nephrogenic diabetes insipidus, auto-
somal dominant polycystic kidney disease (PKDI) and cystinosis
have been identified. Still there remain a large number of
inherited diseases of the kidney for which genetic localization and
disease gene identification are lagging. The rate limiting step in
the achievement of genetic localization for many of these disor-
ders is the availability of a sufficient number of well characterized
families with an adequate number of meloses.
The aim of ISGRD is to bring together a group of clinicians,
geneticists, cellular and molecular biologists, interested in the
study of inherited renal diseases, and enroll them in a concerted
effort designed to accomplish the following objectives:
A) identify and register a sufficient number of patients with
phenotypically well defined inherited renal diseases deemed to be
or to become the subject of scientific inquiry;
B) initiate or facilitate collaborative studies by ISGRD of
specific inherited renal diseases;
C) foster exchange of information among the participants;
D) disseminate the results of the collaborative studies;
E) serve as a resource to investigators whose research activities
are consistent with the goals of the ISGRD.
The initial objective, which has already been accomplished,
entailed the establishment of an electronic data-base. "KidBase"
may be accessed via the World Wide Web (WWW) using one of
several software programs (Mosaic, Netscape or MacWeb). The
URL (address) is: http://www.gdb.org/kidbase.html. So far, entry
forms are on-line for: Bartter's syndrome, cystinuria, and
Laurence-Moon-Bardet-Biedi syndrome. Soon, other conditions
will be added: autosomal recessive polycystic renal disease
(ARPKD), brachio-oto-renal syndrome (Melnick-Fraser syn-
drome), cystinosis, diffuse mesangial sclerosis, distal renal tubular
acidosis, dysencephalia splanchocystica (Meckel-Gruber syn-
drome), nail-patella syndrome, and nephrogenic diabetes insipi-
dus. Any clinician can enter data into KidBase, and any investi-
gator may request access to the information stored in the data-
base.
In addition, ISGRD has started a collaborative study of
Bartter's syndrome, using both positional cloning and candidate
gene based approaches.
The success of the KidBase and of the studies it could engender
will depend to a large extent on the number of patients entered
into the database. We urge all of our colleagues to contribute their
patients. Those who have access to the Internet can do it directly.
Those who do not have access to the Internet may contact the
ISGRD office in USA or Europe. We will enter the data for them.
National Societies
The Secretary General of the International Society of Nephrology
is endeavoring to bring the Society's list of national societies
up-to-date. Many such national societies are not affiliated with the
ISN or their affiliation has lapsed. To retain their affiliated status
and to vote at the General Assembly, a list of individual members
is required to be sent annually. Secretaries of national societies
therefore are asked to provide the Secretary General with the
address to which correspondence should be sent, together with a
list of their officers and individual members, and a formal
application for affiliation where this has lapsed. Please send these
to Jan J. Weening, M.D., Academic Medical Center, Meiberg-
dreef 9, 1105 AZ Amsterdam, The Netherlands.
AWARDS AND GRANTS
International Fellowship Training Awards
The International Society of Nephrology announces the establish-
ment of an International Fellowship Training Program to provide
training in clinical nephrology to physicians from developing coun-
tries. It is the objective of this program to support the growth of
nephrology in developing countries through an educational program
that admits qualified applicants to clinical training in recognized
nephrology programs around the world, and then to return to their
home country to practice and/or teach. In unique circumstances,
applicants who wish basic research training may be considered if the
environment in the home country will permit continued research
upon the completion of training.
The guidelines for application are as follows:
(1) Fellowship awards will be made only to physicians from
developing countries.
(2) Applicants must provide evidence of acceptance into a
recognized and suitable training program before the
award can be granted.
(3) The Fellow must return to his or her home country upon
completion of approved training.
(4) The Fellow must provide evidence of a guaranteed posi-
tion in a medical institution upon return to the home
country.
(5) Fellows will receive a stipend from the Society such that,
taking into account the home country and/or the host
institution support that they may have, they achieve a
$22,500 US revenue.
(6) Fellows must be able to read and speak the language of
the host country. An interview may be required to assess
verbal fluency.
(7) Fellowships will be offered primarily for clinical training of
one to two years duration.
(8) Clinical training programs should be practical in their
orientation, and applicable to the needs and conditions of
the home country. The ability of the host institution to
provide such training will be an important factor in the
selection process.
(9) Fellows must have received sufficient training in internal
medicine or other fields to pass all host country examina-
tions that are necessary to the care of patients. Fellow-
ships may be awarded to senior individuals who seek
additional training but, in general, preference will be given
to younger physicians who are at the beginning of their
permanent careers.
(10) Specific instructions and the necessary application forms
can be obtained by writing directly to Jan J. Weening,
M.D., Academic Medical Center, Meibergdreef 9, 1105
AZ Amsterdam, The Netherlands.
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Kidney International invites brief announcements of meetings,
courses, workshops, and so forth, pertaining to nephrology. Please
send the announcement, complete with dates, location of meeting,
and correspondent's name, address, and phone number 7 months
or more in advance of the time of the event. Announcements are
inserted into the publication schedule when they arrive in the
Editorial Office until the month of the event. Announcements
should be sent to the above-stated address for the Editorial Office
in Little Rock, Arkansas, USA.
Errata
1. Schmidt S, Schöne N, Ritz E, and the Diabetic Nephropathy
Study Group: Association of ACE gene polymorphism and dia-
betic nephropathy? Kidney mt 47:1176-1181.
In the article cited above, appearing in the April issue of the
journal, Table 3B contains an error in the column Type I Diabetes
With Nephropathy. The number of patients with ID should read
25, not 15. All calculations have been performed with the correct
figure. The Editor and Publisher regret the error.
2. Martin P and Friedman LS: Chronic viral hepatitis and the
management of chronic renal failure. Kidney mt 47:1231—1241.
In the article cited above, appearing in the May issue of the
journal, the word "vaccine" was mistakenly omitted from the final
sentence of the paragraph under the heading Role of antiviral
therapy in recipients of renal transplants on page 1237. This
sentence should read as follows:
The apparent inability of the host to mount neutralizing
antibodies suggests that development of an effective HCV vaccine
will be difficult [118].
The Editor and Publisher regret the error.
3. Textor SC, Burnett JC Jr, Romero JC, Canzanello VJ, Taler
SJ, Wiesner R, Porayko M, Krom R, Gores G, and Hay E:
Urinary endothelin and renal vasoconstriction with cyclosporine
or FK506 after liver transplantation. Kidney mt 47:1426—1433.
In the article cited above, appearing in the May issue of the
journal, a mechanical error caused part of page 1431 to be
misprinted. The first few words in the first full paragraph of the
righthand column on that page were deleted. The text of the
paragraph is reproduced in full below.
Most importantly, our results establish that renal endothelin
and prostacyclin excretion are disturbed after liver transplantation
without direct manipulation of the kidney. These changes devel-
oped within a month after transplant and persisted indefinitely.
Unlike studies in experimental animals, several human studies
indicate that prostacyclin is suppressed during CsA administration
[4]. We previously demonstrated this effect in the first several
weeks after transplant during which time renal vasoconstriction
and loss of GFR develops, despite rising arterial pressures and
normalization of previously highly active renin-angiotensin system
[11]. FK506 produces a similar hormonal and renal profile early
after transplantation [3]. Results from the present study indicate
that urinary endothelin increased simultaneously with the sup-
pression of prostacyclin. Whether local release of ET caused the
observed changes in prostacyclin, or vice versa, cannot be estab-
lished with the present data. Nonetheless, these combined effects
subject the renal vasculature to multiple hormonal disturbances
favoring vasoconstriction. The presence of multiple simultaneous
disturbances in the renal vasculature may explain the limited
efficacy of maneuvers to enhance or block a single system, such as
the administration of prostaglandin analogs (misoprostol [31]) or
fish oil to shift the eicosanoid balance from thromboxane produc-
tion [32].
4. Kaysen GA, Rathore V, Shearer GC, and Depner TA:
Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney
mt 48:510—516.
In the article cited above, appearing in the August issue of the
journal, the authors reported an error in Table 1, p. 513, left
column. In this table, under the heading "Acute phase reactants,"
the units for a2-macroglobulin and a1-acid glycoprotein should be
in milligrams per milliliter (mg/mI) rather than in milligrams per
deciliter (mg/dl) with regard to the concentration of a2-macro-
globulin. These corrections do not change the interpretation of
the data; however, they do correct an error in the report of
concentration of these two proteins.
